Menopause, midlife hormones and divorce
Sleeping badly, crying at nothing, losing words mid-sentence, no interest in sex. Every one of those is on the list for divorce and every one is on the list for perimenopause, and if you are between forty-five and fifty-five you may well be having both at once. Attributing all of it to the divorce is how women go five years without being offered treatment that works.
Menopause, Midlife Hormones, and the Overlap With Divorce
Perimenopause and acute divorce stress produce nearly identical symptoms, sleep disruption, mood swings, brain fog, low libido, which means people and their clinicians frequently misattribute one for the other. The science on hormone therapy has moved substantially past the 2002 Women’s Health Initiative panic, and there are now credible non-hormonal options too.
The current position of The Menopause Society is that hormone therapy’s risks and benefits depend heavily on age and time since menopause, not a blanket yes or no for all women, correcting how the original Women’s Health Initiative results were over-generalized.
The Menopause Society’s 2022 hormone therapy position statement holds that for most healthy symptomatic women who are under 60 or within 10 years of menopause onset, the benefits of hormone therapy for treating hot flashes and related symptoms generally outweigh the risks. For women older than 60 or more than 10 to 20 years past menopause, risk of cardiovascular disease, stroke, blood clots, and dementia is comparatively higher, and the balance shifts. This individualized approach replaced the earlier blanket caution that followed the 2002 Women’s Health Initiative trial, whose findings on older, mostly post-65 participants were widely misapplied to all menopausal women regardless of age or timing.
There is now an FDA-approved non-hormonal medication specifically for moderate to severe hot flashes, giving women who cannot or prefer not to use hormone therapy a real evidence-based option.
Fezolinetant (brand name Veozah) was approved by the FDA in May 2023 as the first neurokinin 3 receptor antagonist for moderate to severe vasomotor symptoms of menopause. It works by blocking a receptor involved in the brain’s temperature regulation and contains no hormones, making it an option for women with a history of hormone-sensitive cancers or other contraindications to hormone therapy.
Sleep disruption, mood swings, brain fog, and low libido are core, well-documented perimenopause symptoms, which is exactly why they get misattributed to divorce stress and vice versa.
Reported consistently, not settled
Perimenopause is defined clinically by fluctuating estrogen and progesterone that commonly produce sleep disturbance, mood lability, cognitive complaints often described as brain fog, and reduced libido, often years before periods stop entirely. Because these same symptoms are also classic responses to major relationship loss and chronic stress, clinicians and patients alike frequently attribute the symptoms entirely to one cause when both may be contributing, which delays proper treatment of either.
Diagnosing low testosterone in men requires blood testing and symptoms together, not symptoms alone, but many commercial “low T” clinics market and treat based on symptoms and marketing rather than confirmed diagnostic criteria.
The Endocrine Society’s clinical practice guideline calls for diagnosing male hypogonadism only in men with both consistent symptoms and unequivocally low serum testosterone confirmed on repeated morning blood tests, and recommends against routine population-wide screening or treatment based on symptoms alone. This is the clinical standard that commercial testosterone clinics marketing to midlife men frequently do not follow, often testing once, at any time of day, and prescribing based on symptom checklists.
The Menopause Society’s current position is that for most healthy women under 60 or within 10 years of menopause onset, the benefits of hormone therapy for symptom relief generally outweigh the risks. The original WHI results, largely from older, post-65 participants, were over-generalized to younger, recently menopausal women for whom the risk profile is different.
The North American Menopause Society (The Menopause Society) Advisory Panel, 2022, Menopause
Fatigue, mood changes, and low libido have many causes, including the acute stress of divorce, poor sleep, depression, and alcohol use. The Endocrine Society requires confirmed, repeatedly low testosterone levels alongside specific symptoms before diagnosing hypogonadism, a bar many commercial low-T clinics do not meet.
Bhasin S, Brito JP, Cunningham GR, et al., 2018, Journal of Clinical Endocrinology and Metabolism
What to actually do
- If sleep, mood, brain fog, or libido changes appear during your 40s or early 50s while going through a divorce, ask a clinician to evaluate for perimenopause specifically rather than assuming it is all situational stress.
- If you are within 10 years of menopause onset and under 60, and hot flashes or other symptoms are significant, ask your doctor about hormone therapy as a legitimate option rather than ruling it out because of decades-old headlines.
- If hormone therapy is not appropriate for you, ask specifically about fezolinetant (Veozah) or other non-hormonal options for hot flashes.
- Be skeptical of any testosterone clinic that diagnoses and prescribes from a single blood draw or a symptom questionnaire without repeat morning testing.
- Do not assume every midlife symptom is either “just the divorce” or “just menopause”; both can be happening simultaneously and each deserves its own evaluation.
- Hormone therapy and testosterone therapy both carry real risks and are not appropriate for everyone; decisions should be individualized with a clinician, not based on marketing from a specialty clinic.